Add time:07/30/2019         Source:sciencedirect.com

BackgroundTumor lysis syndrome (TLS) is a life-threatening disorder that occurs mainly in patients with high-tumor burden hemato-oncologic malignancies. It results in metabolic derangements, including hyperuricemia and acute renal failure. The powerful management for TLS is a daily dose of Rasburicase (cas 134774-45-1) for up to 5 days before chemotherapy; however, the optimal dose and duration of rasburicase for TLS prophylaxis have not been standardized for patients at high risk for TLS. Therefore, we evaluated the efficacy of single-dose rasburicase for prophylactic purposes in patients with malignant lymphoma at high risk for TLS.

We also recommend Trading Suppliers and Manufacturers of Rasburicase (cas 134774-45-1). Pls Click Website Link as below: cas 134774-45-1 suppliers